Wave spot­lights ‘pos­i­tive’ da­ta on Hunt­ing­ton’s drug, but stock takes a beat­ing as Roche, Io­n­is ri­val stays in front

Wave Life Sci­ences put the most pos­i­tive spin pos­si­ble on a snap­shot of da­ta from their Hunt­ing­ton’s dis­ease study, but on­ly man­aged to scare in­vestors as an­a­lysts ques­tioned the da­ta and how it stacks up against a key ri­val.

Shares $WVE dropped by 50% as com­pa­ny ex­ecs sought to ex­plain them­selves in a call Mon­day morn­ing.

Pulling out the co­hort da­ta from the 16 mg high dose of WVE-120102 in the Phase Ia/IIb tri­al, in­ves­ti­ga­tors found a p val­ue of 0.03, enough to squeeze past the end­point on sta­tis­ti­cal sig­nif­i­cance. Over­all, there was a 12.4% drop in mu­tant hunt­ingtin pro­tein in pa­tients’ spinal flu­id. And they sug­gest­ed they could do bet­ter with a 32 mg dose.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER